Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00885963 · ClinicalTrials.gov registry record · Phase 2
A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 62
- Enrollment target
NCT00885963 is a Phase 2 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 62 participants.
The verdict
NCT00885963, a Phase 2 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 62 participants
- Enrollment target
Study Summary
A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
Interventions
- DRUG sapacitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 62 participants |
| Start Date | 2008-12-01 |
| Est. Completion | 2013-12-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00885963
The ClinicalTrials.gov registry entry for NCT00885963 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 62 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cyclacel Pharmaceuticals, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which sapacitabine is the first listed.
NCT00885963 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00885963 about?
NCT00885963 is a clinical study titled "A Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer". A phase II study to evaluate the safety and efficacy of oral sapacitabine in previously treated advanced non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00885963?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 62 participants. The study started on 2008-12-01. Estimated completion is 2013-12-23.
What interventions are being tested in trial NCT00885963?
The interventions under investigation include: sapacitabine (DRUG).
Who is sponsoring clinical trial NCT00885963?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.